The research progress of SEPT9 in the early detection of colorectal cancer

doi:10.3877/cma.j.issn.2095-3224.2019.05.011

Abstract

Abstract:

SEPT9 is one of the 13 Septin homologous gene families involved in regulating numerous processes, including cell division, cell polarization, cell migration and mitochondrial division. Studies have shown that in many tumors, SEPT9 plays a role, especially in the field of colorectal cancer research, peripheral blood SEPT9 gene methylation detection is the research hotspot, the detection sensitivity and speciality rate relative to other glycoprotein tumor markers, fecal occult blood test and a fecal immunochemical test has more advantages, relative to colorectal colonoscopy invasive procedures it was more cost savings, at the same time with better compliance. This paper reviews the function of SEPT9, the relationship between SEPT9 and colorectal cancer, as well as the screening and diagnostic value of colorectal cancer.

Key words: Colorectal neoplasms, SEPT9, Colorectal cancer screening, DNA methylation

Hongyu Yang, Fuquan Yang. The research progress of SEPT9 in the early detection of colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2019, 08(05): 496-500.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2019.05.011

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2019/V08/I05/496

References 49

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018 [J]. CA Cancer J Clin, 2018, 68(1): 7-30.
[2]	Vatandoost N, Ghanbari J, Mojaver M, et al. Early detection of colorectal cancer: from conventional methods to novel biomarkers [J]. J Cancer Res Clin Oncol. 2016, 142(2):341-351.
[3]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2):115-132.
[4]	Song L, Jia J, Peng X, et al. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis [J]. Scientific Reports, 2017, 7(1): 3032.
[5]	Yan S, Liu Z, Yu S, et al. Diagnostic value of methylated Septin9 for colorectal cancer screening: A meta-analysis [J]. Medical Science Monitor International Medical Journal of Experimental & Clinical Research, 2016, 22: 3409-3418.
[6]	Sandrock K, Bartsch I, Bläser S, et al. Characterization of human septin interactions [J]. Biological Chemistry, 2011, 392(8-9): 751-761.
[7]	Oliva P, Maha EZ, Trimble WS. Uncovering the roles of Septins in Cilia [J]. Frontiers in Cell and Developmental Biology, 2017, 5: 36.
[8]	Russell SEH, Hall PA. Septin genomics: a road less travelled [J]. Biological Chemistry, 2011, 392(8-9)
[9]	Kojima K, Sakai I, Hasegawa A, et al. FLJ10849, a septin family gene, fuses MLL in a novel leukemia cell line CNLBC1 derived from chronic neutrophilic leukemia in transformation with t(4;11)(q21;q23) [J]. LEUKEMIA, 2004, 18(5): 998-1005.
[10]	Connolly D, Yang Z, Castaldi M, et al. Septin 9 isoform expression, localization and epigenetic changes during human and mouse breast cancer progression [J]. Breast Cancer Research, 2011, 13(4): R76.
[11]	Kim DS, Hubbard SL, Peraud A, et al. Analysis of mammalian Septin expression in human malignant brain tumors [J]. Neoplasia, 2004, 6(2): 168-178.
[12]	Behrouz Sharif S, Hashemzadeh S, Mousavi Ardehaie R, et al. Detection of aberrant methylated SEPT9 and NTRK3 genes in sporadic colorectal cancer patients as a potential diagnostic biomarker [J]. Oncol Lett, 2016, 12(6): 5335-5343.
[13]	Wasserkort R, Kalmar A, Valcz G, et al. Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island [J]. BMC Cancer, 2013, 13(1): 398.
[14]	Tóth Kinga, Ferenc S, Kalmár Alexandra, et al. Detection of methylated SEPT9 in plasma Is a reliable screening method for both left-and right-sided colon cancers [J]. PLoS ONE, 2012, 7(9): e46000.
[15]	Wu D, Zhou G, Jin P, et al. Detection of colorectal cancer using a simplified SEPT9 gene methylation assay is a reliable method for opportunistic screening [J]. J Mol Diagn, 2016, 18(4): 535-545.
[16]	Song L, Li Y, Jia J, et al. Algorithm optimization in methylation detection with multiple RT-qPCR [J]. PLoS One, 2016, 11(11): e0163333.
[17]	Lofton-Day C, Model F, Devos T, et al. DNA Methylation Biomarkers for Blood-Based Colorectal Cancer Screening [J]. Clinical Chemistry, 2008, 54(2): 414-423.
[18]	Lee HS, Hwang SM, Kim TS, et al. Circulating methylated Septin 9 nucleic acid in the plasma of patients with gastrointestinal cancer in the stomach and colon [J]. Transl Oncol, 2013, 6(3): 290-296.
[19]	Lin JS, Piper MA, Perdue LA, et al. Screening for colorectal cancer: updated evidence report and systematic review for the US preventive services task force [J]. JAMA, 2016, 315(23): 2576-2594.
[20]	Issa IA, Noureddine M. Colorectal cancer screening: An updated review of the available options [J]. World J Gastroenterol, 2017, 23(28): 5086-5096.
[21]	Rex DK, Bond JH, Winawer S,et al. Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: recommendations of the U.S. Multi-Society Task Force on Colorectal Cancer [J]. Am J Gastroenterol, 2002, 97(6): 1296-1308.
[22]	Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer [J]. N Engl J Med, 2010, 362(19): 1795-1803.
[23]	Lieberman D. A call to action-measuring the quality of colonoscopy [J]. N Engl J Med, 2006, 355(24): 2588-2589.
[24]	Eisen GM, Dominitz JA, Baron TH, et al. Complications of colonoscopy [J]. Gastrointest Endosc, 2003, 57: 441-445.
[25]	Carmona FJ, Azuara D, Berenguer-Llergo A, et al. DNA methylation biomarkers for noninvasive diagnosis of colorectal cancer [J]. Cancer Prev Res (Phila), 2013, 6(7): 656-665.
[26]	Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies [J]. BMJ, 2014, 348: g2467.
[27]	Scholefield JH, Moss SM, Mangham CM, et al. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up [J]. Gut, 2012, 61(7): 1036-1040.
[28]	Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer [J]. Br J Surg, 2008, 95(8): 1029-1036.
[29]	Young GP, Symonds EL, Allison JE, et al. Advances in fecal occult blood tests: the FIT revolution [J]. Dig Dis Sci, 2015, 60(3): 609-622.
[30]	Bretthauer M. Colorectal cancer screening [J]. J Intern Med, 2011, 270(2): 87-98.
[31]	Lee JK, Liles EG, Bent S, et al. Accuracy of fecal immunochemical tests for colorectal cancer [J]. Annals of Internal Medicine, 2014, 160(3): 171-181.
[32]	Fraser CG, Halloran SP, Allison JE, et al. Making colorectal cancer screening FITTER for purpose with quantitative faecal immunochemical tests for haemoglobin (FIT) [J]. Clin Chem Lab Med, 2013, 51(11): 2065-2067.
[33]	Wild N, Andres H，Rollinger W, et al. A combination of serum markers for the early detection of colorectal cancer [J]. Clinical Cancer Research, 2010, 16(24): 6111-6121.
[34]	Chen JS, Chen KT, Fan WC, et al. Combined analysis of survivin autoantibody and carcinoembryonic antigen biomarkers for improved detection of colorectal cancer [J]. Clin Chem Lab Med, 2010, 48(5): 719-725.
[35]	Yu H, Son GM, Joh YG. The clinical significance of preoperative serum levels of carbohydrate antigen 19-9 in colorectal cancer [J]. J Korean Surg Soc, 2013, 84(4): 231-237.
[36]	Adler A, Geiger S, Keil A, et al. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany [J]. BMC Gastroenterol, 2014, 14(1): 183.
[37]	Hong-Bing FU, Wei-Min W. The application of combined defection of serum tumor markers levels of patients with colon cancer [J]. Chinese Journal of Clinicians, 2012, 6(17): 5087-5090.
[38]	Zhang Y, Yang J, Li H, et al. Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis [J]. Int J Clin Exp Med, 2015, 8(7): 11683-11691.
[39]	Luka de Vos, Heidrun Gevensleben, Andreas Schröck, et al. Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients [J]. Clin Epigenetics, 2017, 9(1): 125.
[40]	Dutruel C, Bergmann F, Rooman I, et al. Early epigenetic downregulation of WNK2 kinase during pancreatic ductal adenocarcinoma development [J]. Oncogene, 2013, 33(26): 3401-3410.
[41]	Laird PW. The power and the promise of DNA methylation markers [J]. Nat Rev Cancer, 2003, 3(4): 253-266.
[42]	Liggett TE, Melnikov A, Yi Q, et al. Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors [J]. Gynecol Oncol, 2011, 120(1): 113-120.
[43]	Zhu H, Bhagatwala J, Huang Y, et al. Race/Ethnicity-Specific Association of Vitamin D and Global DNA Methylation: Cross-Sectional and Interventional Findings [J]. PLoS One, 2016, 11(4): e0152849.
[44]	Zhang M, He Y, Zhang X, et al. A pooled analysis of the diagnostic efficacy of plasmic methylated septin-9 as a novel biomarker for colorectal cancer [J]. Biomed Rep, 2017, 7(4): 353-360.
[45]	Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylatedSEPT9in plasma for detection of asymptomatic colorectal cancer [J]. Gut, 2014, 63(2): 317-325.
[46]	Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins [J]. Proc Natl Acad Sci U S A, 2005, 102(30): 10604-10609.
[47]	Keating ST, El-Osta A. Epigenetics and metabolism [J]. Circ Res, 2015, 116(4): 715-736.
[48]	Mai-Britt W, Hans J, Torben F, et al. Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study [J]. BMC Cancer, 2015, 15(1): 819.
[49]	He N, Song L, Kang Q, et al. The Pathological Features of Colorectal Cancer Determine the Detection Performance on Blood ctDNA [J]. Technol Cancer Res Treat, 2018, 17 : 1533033818791794.

Please choose a citation manager

Content to export